We are live on
!
Find out more
DCM
DAFNA Capital Management Portfolio holdings
AUM
$524M
1-Year Est. Return
164.42%
This Fund
S&P 500
This Quarter
Est. Return
-1.96%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$114M
AUM Growth
-$29.8M
(-21%)
Cap. Flow
-$27M
Cap. Flow
% of AUM
-23.68%
Top 10 Holdings %
Top 10 Hldgs %
42.25%
Holding
85
New
11
Increased
13
Reduced
16
Closed
19
Avg Time Held
5.7
quarters
Top 10 Avg Time Held
3.6
quarters
Top 20 Avg Time Held
4.5
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Viracta Therapeutics, Inc. Common Stock
VIRX
|
+$4.51M |
| 2 |
iShares Biotechnology ETF
IBB
|
+$2.38M |
| 3 |
Blueprint Medicines
BPMC
|
+$2.19M |
| 4 |
Cidara Therapeutics
CDTX
|
+$1.66M |
| 5 |
ADXS
Advaxis Inc
ADXS
|
+$1.57M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
|
+$15M |
| 2 |
CYNA
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
|
+$9.26M |
| 3 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$2.15M |
| 4 |
BSTC
BioSpecifics Technologies Corp.
BSTC
|
+$1.81M |
| 5 |
TSRO
TESARO, Inc.
TSRO
|
+$1.77M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.3% |
| 2 | Miscellaneous | 6.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
AtriCure
ATRC
$2.89B
| $10.2M | 8.92% |
518,946
-10,000
| -2% | -$181K |
2013 Q2
14 quarters
|
|
|
NXTM
2
DELISTED
NxStage Medical Inc.
NXTM
| $6.19M | 5.44% |
236,119
-2,390
| -1% | -$59.1K |
2013 Q2
14 quarters
|
|
|
ALDR
3
DELISTED
Alder Biopharmaceuticals
ALDR
| $4.6M | 4.04% |
221,013
+55,700
| +34% | +$1.45M |
2015 Q3
5 quarters
|
|
|
LOXO
4
DELISTED
Loxo Oncology, Inc
LOXO
| $4.49M | 3.94% |
139,722
+9,500
| +7% | +$244K |
2015 Q2
6 quarters
|
|
5
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.9B
| $4.24M | 3.73% |
66,068
| – | – |
2015 Q3
5 quarters
|
|
|
6
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $4.1M | 3.61% |
+32,388
| New | +$4.51M |
2016 Q4
0 quarters
|
|
7
Xenon Pharmaceuticals
XENE
$3.33B
| $3.96M | 3.48% |
514,091
| – | – |
2015 Q3
5 quarters
|
|
|
AERI
8
DELISTED
Aerie Pharmaceuticals
AERI
| $3.72M | 3.27% |
98,370
+6,501
| +7% | +$246K |
2014 Q3
9 quarters
|
|
9
BeOne Medicines Ltd
ONC
$39.5B
| $3.64M | 3.2% |
119,841
+29,699
| +33% | +$933K |
2016 Q1
3 quarters
|
|
10
DELISTED
Dermira, Inc.
DERM
| $3M | 2.63% |
98,800
| – | – |
2016 Q1
3 quarters
|
|
|
FOMX
11
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $2.98M | 2.61% |
268,067
-10,000
| -4% | -$94.1K |
2015 Q4
4 quarters
|
|
12
Insulet
PODD
$9.58B
| $2.77M | 2.43% |
73,484
| – | – |
2013 Q2
14 quarters
|
|
|
AGTC
13
DELISTED
Applied Genetic Technologies Corporation
AGTC
| $2.68M | 2.35% |
286,298
+46,000
| +19% | +$414K |
2015 Q1
7 quarters
|
|
14
Cytokinetics
CYTK
$8.57B
| $2.56M | 2.24% |
210,306
+28,569
| +16% | +$303K |
2015 Q4
4 quarters
|
|
15
Neurocrine Biosciences
NBIX
$13.7B
| $2.56M | 2.24% |
66,008
+2,000
| +3% | +$90.5K |
2016 Q1
3 quarters
|
|
16
Ardelyx
ARDX
$806M
| $2.47M | 2.17% |
173,995
-45,100
| -21% | -$640K |
2016 Q1
3 quarters
|
|
|
17
iShares Biotechnology ETF
IBB
$10.2B
| $2.31M | 2.03% |
+26,100
| New | +$2.38M |
2016 Q4
0 quarters
|
|
|
TSRO
18
DELISTED
TESARO, Inc.
TSRO
| $2.08M | 1.83% |
15,500
-14,000
| -47% | -$1.77M |
2016 Q2
2 quarters
|
|
|
IMMU
19
DELISTED
Immunomedics Inc
IMMU
| $2.05M | 1.8% |
559,674
-7,122
| -1% | -$21.1K |
2016 Q2
2 quarters
|
|
20
DELISTED
Radius Health, Inc.
RDUS
| $2.05M | 1.8% |
53,854
+17,000
| +46% | +$809K |
2016 Q1
3 quarters
|
|
|
21
DELISTED
Blueprint Medicines
BPMC
| $2.03M | 1.79% |
+72,500
| New | +$2.19M |
2016 Q4
0 quarters
|
|
22
Tvardi Therapeutics
TVRD
$13.9M
| $1.95M | 1.71% |
5,820
-1,598
| -22% | -$513K |
2015 Q2
6 quarters
|
|
|
DSCI
23
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
| $1.84M | 1.62% |
353,718
| – | – |
2013 Q2
14 quarters
|
|
24
MacroGenics
MGNX
$218M
| $1.82M | 1.6% |
89,200
+35,000
| +65% | +$881K |
2015 Q3
5 quarters
|
|
25
DELISTED
BioTelemetry, Inc.
BEAT
| $1.68M | 1.47% |
75,000
-5,000
| -6% | -$97.8K |
2013 Q2
14 quarters
|
|
Similar funds
4WM
BB
A
HW
DAM
SDWIA
SCA
BHPW
DAFNA Capital Management's Q4 2016 Portfolio in Review
As of Q4 2016, DAFNA Capital Management held 85 positions worth $114M, down 21% from $144M the previous quarter. Its ten largest holdings account for 42% of the portfolio.
DAFNA Capital Management withdrew a net $27M in Q4 2016, closing 19 positions and reducing 16 holdings. Its most notable exit was VITAE PHARMACEUTICALS INC COMMON STOCK, an estimated $15M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 79% a quarter earlier, followed by Miscellaneous.
Against the trend, DAFNA Capital Management opened a new position in Viracta Therapeutics, Inc. Common Stock worth $4.1M.
- DAFNA Capital Management's largest Q4 2016 buy was Viracta Therapeutics, Inc. Common Stock: 32,388 shares worth $4.1M.
- DAFNA Capital Management added most to Alder Biopharmaceuticals in Q4 2016, an estimated $1.45M increase.
- DAFNA Capital Management's biggest Q4 2016 reduction was TESARO, Inc., cutting an estimated $1.77M.
- DAFNA Capital Management fully exited VITAE PHARMACEUTICALS INC COMMON STOCK in Q4 2016, selling an estimated $15M.
- DAFNA Capital Management's ten largest holdings make up 42% of its $114M portfolio in Q4 2016.
- DAFNA Capital Management opened 11 new positions and closed 19 in Q4 2016.
- DAFNA Capital Management's portfolio value fell 21% quarter-over-quarter to $114M.
Based on DAFNA Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.